Post-approval studies (Phase 4)Study completedNCT01821911
What this trial is testing
The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use
Who this might be right for
Rabies Vaccine AllergyVaccination Adverse EventAnti-D Antibodies
Beijing Center for Disease Control and Prevention 10,500